298 related articles for article (PubMed ID: 9204055)
1. Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and pemphigus foliaceus.
Brenner S; Bialy-Golan A; Anhalt GJ
J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):919-23. PubMed ID: 9204055
[TBL] [Abstract][Full Text] [Related]
2. The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic.
Ding X; Diaz LA; Fairley JA; Giudice GJ; Liu Z
J Invest Dermatol; 1999 May; 112(5):739-43. PubMed ID: 10233765
[TBL] [Abstract][Full Text] [Related]
3. Identification of a new antibody population directed against a desmosomal plaque antigen in pemphigus vulgaris and pemphigus foliaceus.
Joly P; Gilbert D; Thomine E; Zitouni M; Ghohestani R; Delpech A; Lauret P; Tron F
J Invest Dermatol; 1997 Apr; 108(4):469-75. PubMed ID: 9077476
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses.
Sami N; Bhol KC; Ahmed AR
Clin Exp Immunol; 2001 Sep; 125(3):492-8. PubMed ID: 11531959
[TBL] [Abstract][Full Text] [Related]
5. Development of pemphigus vulgaris in a patient with pemphigus foliaceus: antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay.
Ishii K; Amagai M; Ohata Y; Shimizu H; Hashimoto T; Ohya K; Nishikawa T
J Am Acad Dermatol; 2000 May; 42(5 Pt 2):859-61. PubMed ID: 10767686
[TBL] [Abstract][Full Text] [Related]
6. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris.
Mahoney MG; Wang Z; Rothenberger K; Koch PJ; Amagai M; Stanley JR
J Clin Invest; 1999 Feb; 103(4):461-8. PubMed ID: 10021453
[TBL] [Abstract][Full Text] [Related]
7. D-penicillamine-induced pemphigus foliaceus with autoantibodies to desmoglein-1.
Brenner S; Ruocco V
J Am Acad Dermatol; 1998 Jul; 39(1):137-8. PubMed ID: 9674417
[No Abstract] [Full Text] [Related]
8. Pemphigus foliaceus and pemphigus vulgaris autoantibodies react with the extracellular domain of desmoglein-1.
Emery DJ; Diaz LA; Fairley JA; Lopez A; Taylor AF; Giudice GJ
J Invest Dermatol; 1995 Mar; 104(3):323-8. PubMed ID: 7860995
[TBL] [Abstract][Full Text] [Related]
9. A case of pemphigus vulgaris showing reactivity with pemphigus antigens (Dsg1 and Dsg3) and desmocollins.
Hashimoto T; Amagai M; Watanabe K; Dmochowski M; Chidgey MA; Yue KK; Garrod DR; Nishikawa T
J Invest Dermatol; 1995 Apr; 104(4):541-4. PubMed ID: 7706774
[TBL] [Abstract][Full Text] [Related]
10. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice.
Amagai M; Nishikawa T; Nousari HC; Anhalt GJ; Hashimoto T
J Clin Invest; 1998 Aug; 102(4):775-82. PubMed ID: 9710446
[TBL] [Abstract][Full Text] [Related]
11. The transition of pemphigus vulgaris into pemphigus foliaceus: a reflection of changing desmoglein 1 and 3 autoantibody levels in pemphigus vulgaris.
Harman KE; Gratian MJ; Shirlaw PJ; Bhogal BS; Challacombe SJ; Black MM
Br J Dermatol; 2002 Apr; 146(4):684-7. PubMed ID: 11966706
[TBL] [Abstract][Full Text] [Related]
12. Decline of anti-desmoglein 1 IgG ELISA scores by withdrawal of D-penicillamine in drug-induced pemphigus foliaceus.
Nagao K; Tanikawa A; Yamamoto N; Amagai M
Clin Exp Dermatol; 2005 Jan; 30(1):43-5. PubMed ID: 15663502
[TBL] [Abstract][Full Text] [Related]
13. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile.
Amagai M; Tsunoda K; Zillikens D; Nagai T; Nishikawa T
J Am Acad Dermatol; 1999 Feb; 40(2 Pt 1):167-70. PubMed ID: 10025740
[TBL] [Abstract][Full Text] [Related]
14. Herpetiform pemphigus showing reactivity with pemphigus vulgaris antigen (desmoglein 3).
Kubo A; Amagai M; Hashimoto T; Doi T; Higashiyama M; Hashimoto K; Yoshikawa K
Br J Dermatol; 1997 Jul; 137(1):109-13. PubMed ID: 9274636
[TBL] [Abstract][Full Text] [Related]
15. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles.
Ding X; Aoki V; Mascaro JM; Lopez-Swiderski A; Diaz LA; Fairley JA
J Invest Dermatol; 1997 Oct; 109(4):592-6. PubMed ID: 9326396
[TBL] [Abstract][Full Text] [Related]
16. Immunofluorescence and immunoblot studies on the reactivity of pemphigus vulgaris and pemphigus foliaceus sera with desmoglein 3 and desmoglein 1.
Hashimoto T; Amagai M; Garrod DR; Nishikawa T
Epithelial Cell Biol; 1995; 4(2):63-9. PubMed ID: 8688919
[TBL] [Abstract][Full Text] [Related]
17. A subset of pemphigus foliaceus patients exhibits pathogenic autoantibodies against both desmoglein-1 and desmoglein-3.
Arteaga LA; Prisayanh PS; Warren SJ; Liu Z; Diaz LA; Lin MS;
J Invest Dermatol; 2002 May; 118(5):806-11. PubMed ID: 11982757
[TBL] [Abstract][Full Text] [Related]
18. The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme-linked immunosorbent assay.
Komai A; Amagai M; Ishii K; Nishikawa T; Chorzelski T; Matsuo I; Hashimoto T
Br J Dermatol; 2001 Jun; 144(6):1177-82. PubMed ID: 11422038
[TBL] [Abstract][Full Text] [Related]
19. An experience for ELISA for desmoglein 1, suggesting a possible diagnostic help to determine the initial therapy for pemphigus foliaceus.
Aoyama Y; Tsujimura Y; Funabashi M; Sato M; Kamiya H; Kitajima Y
Eur J Dermatol; 2000; 10(1):18-21. PubMed ID: 10694292
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus.
Korman NJ; Eyre RW; Zone J; Stanley JR
J Invest Dermatol; 1991 Feb; 96(2):273-6. PubMed ID: 1991988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
